We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
In-House Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-Small Cell Lung Cancer and Melanoma Patients.
- Authors
Heeke, Simon; Benzaquen, Jonathan; Long-Mira, Elodie; Audelan, Benoit; Lespinet, Virginie; Bordone, Olivier; Lalvée, Salomé; Zahaf, Katia; Poudenx, Michel; Humbert, Olivier; Montaudié, Henri; Dugourd, Pierre-Michel; Chassang, Madleen; Passeron, Thierry; Delingette, Hervé; Marquette, Charles-Hugo; Hofman, Véronique; Stenzinger, Albrecht; Ilié, Marius; Hofman, Paul
- Abstract
Tumor mutational burden (TMB) has emerged as an important potential biomarker for prediction of response to immune-checkpoint inhibitors (ICIs), notably in non-small cell lung cancer (NSCLC). However, its in-house assessment in routine clinical practice is currently challenging and validation is urgently needed. We have analyzed sixty NSCLC and thirty-six melanoma patients with ICI treatment, using the FoundationOne test (FO) in addition to in-house testing using the Oncomine TML (OTML) panel and evaluated the durable clinical benefit (DCB), defined by >6 months without progressive disease. Comparison of TMB values obtained by both tests demonstrated a high correlation in NSCLC (R2 = 0.73) and melanoma (R2 = 0.94). The association of TMB with DCB was comparable between OTML (area-under the curve (AUC) = 0.67) and FO (AUC = 0.71) in NSCLC. Median TMB was higher in the DCB cohort and progression-free survival (PFS) was prolonged in patients with high TMB (OTML HR = 0.35; FO HR = 0.45). In contrast, we detected no differences in PFS and median TMB in our melanoma cohort. Combining TMB with PD-L1 and CD8-expression by immunohistochemistry improved the predictive value. We conclude that in our cohort both approaches are equally able to assess TMB and to predict DCB in NSCLC.
- Subjects
LUNG cancer treatment; MELANOMA treatment; BIOMARKERS; CANCER patients; CONFIDENCE intervals; IMMUNOTHERAPY; MONOCLONAL antibodies; GENETIC mutation; TREATMENT effectiveness
- Publication
Cancers, 2019, Vol 11, Issue 9, p1271
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers11091271